Altamira Therapeutics Receives Letter From Nasdaq Qualifications Department That It Is No Longer In Compliance
Altamira Therapeutics Receives Letter From Nasdaq Qualifications Department That It Is No Longer In Compliance
Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that it no longer complied with Rule 5550(a)(2) of Nasdaq's Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company's listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. The letter stated that the Company is not eligible for any cure period due to the fact that the Company effectuated one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. The Company intends to appeal this determination to a hearing panel (the "Panel"). The hearing request will result in a stay of any suspension or delisting action pending the hearing. There can be no assurance that the Panel will grant the Company's request for continued listing or that any extension will be granted by the Panel.
Altamira Therapeutics Ltd.（"Altamira"或"公司"）（納斯達克股票代碼：CYTO）今日宣佈，於2024年9月30日收到了納斯達克股份市場有限責任公司（"納斯達克"）上市資格部門的一封信，內容指出公司不再符合納斯達克的上市規則第5550(a)(2)條的規定。該規定要求上市證券維持每股最低1.00美元的最低買盤價格，因爲該公司上市證券的買盤價格在2024年8月16日至2024年9月27日期間的前30個連續業務日內收於1.00美元以下。信函指出，由於該公司在過去兩年內實施了一項或多項拆股並股業務，總比率爲250股或更多合一。公司打算向一個聽證小組（"小組"）上訴這一決定。提出聽證請求將導致停止任何暫停或除牌行動，等待聽證。無法保證小組會批准公司繼續上市的要求，或者小組會批准延長任何期限。
